We are live on ! Find out more

RenovoRx

RNXT

Market cap $56.5M

1.17 USD

-0.01

0.85%

At close Updated Nov 10, 9:39 AM EST

1 day

-0.85%

5 days

-12.03%

1 month

-6.4%

3 months

0.86%

6 months

37.65%

Year to date

40.09%

1 year

17.45%

5 years

-85.66%

10 years

-83.88%

About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Employees: 17

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.3%

Neutral 87.5%

Negative 6.3%

RenovoRx Q3 Earnings Call Highlights

RenovoRx NASDAQ: RNXT reported record third-quarter 2026 revenue of $1.07 million, exceeding $1 million in quarterly sales for the first time as more cancer centers adopted its RenovoCath drug-delivery device.

RenovoRx Q3 Earnings Call Highlights

RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript

RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript

RenovoRx, Inc. (RNXT) Q3 2026 Earnings Call Transcript

Zacks Investment Research

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.

RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion Using TAMP Beyond Locally Advanced Pancreatic Cancer, Signaling Potential for Broader Clinical Adoption Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif.

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, are scheduled to present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum being held on November 11, 2026 in New York, NY.

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

MOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026.

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical Resection

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC Case Series Reports Tumor Treatment Response, Significant Tumor Marker Reduction, and Changes on Imaging After Treatment with TAMP in Patients with Unresectable LAPC

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C.

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Levels and Tumor Marker Reduction MOUNTAIN VIEW, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the journal Cancer Chemotherapy and Pharmacology.

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

See News Rankings

Price charts implemented using Lightweight Charts™